MedTrace Logo

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

NCT04601610 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-10-28

No results posted yet for this study

Summary

This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced hepatocellular carcinoma.

Conditions

  • Advanced HCC

Interventions

DRUG

KN046 （PD-L1/CTLA4 BsAb）

KN046 5mg/kg Q3W

DRUG

Ningetinib Tosylate（multi-target TKI）

ningtinib QD, dose will be decided by investigator

Sponsors & Collaborators

  • Sunshine Lake Pharma Co., Ltd.

    collaborator INDUSTRY

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • JianMing Xu, Doctor · 301 Hospital of PLA，Beijing，China

  • ShanZhi Gu, Doctor · Hunan Cancer Hospital

  • YuXian Bai, Doctor · Harbin Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2022-05-30
Completion
2022-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601610 on ClinicalTrials.gov